Levosulpiride is a substituted benzamide, which exerts antidopaminergic (selective dopamine D2 receptors) activity on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent.

Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3 hr.
Excretion: Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV).

Information Not Available

Amenorrhoea, gynaecomastia, galactorrhoea, changes in libido.
Potentially Fatal: Neuroleptic malignant syndrome.

Information Not Available

May impair ability to drive or operate machinery. Pregnancy and lactation

Reduced bioavailability with sucralfate, aluminium- and magnesium-containing antacids. Effect on GI motility may be antagonised by anticholinergic agents, narcotics and analgesics. Avoid alcohol.

Information Not Available

Oral
Gastro-oesophageal reflux disease, Irritable bowel syndrome, Dyspepsia
Adult: 25 mg tid.
Elderly: Dose reductions may be necessary.

Information Not Available

Caution when used during pregnancy

Caution when used during lactation

Information Not Available

Information Not Available

Phaeochromocytoma, epilepsy, manic states, hyperprolactinaemia, mammary dysplasia, malignant mastopathies, cardiac impairment. GI bleeding, mechanical obstruction or perforation.

Oral: Store at 15-30°C (59-86°F)

Information Not Available